Comparative Pharmacology
Head-to-head clinical analysis: DROXIA versus TAZVERIK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROXIA versus TAZVERIK.
DROXIA vs TAZVERIK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyurea inhibits ribonucleotide reductase, depleting deoxyribonucleotides and inducing fetal hemoglobin (HbF) synthesis.
TAZVERIK is a histone methyltransferase EZH2 inhibitor. It selectively inhibits the enzymatic activity of EZH2, leading to decreased trimethylation of lysine 27 on histone H3 (H3K27me3), which results in reactivation of silenced genes and inhibition of proliferation in EZH2-mutant or wild-type cells.
Hydroxyurea (Drosia) for sickle cell anemia: Oral, starting dose 15 mg/kg once daily; escalate by 5 mg/kg every 12 weeks to maximum 35 mg/kg/day. For essential thrombocythemia: 15-30 mg/kg once daily. For myelodysplastic syndrome: 15-30 mg/kg once daily.
600 mg orally twice daily, with or without food, for advanced epithelioid sarcoma. Continue until disease progression or unacceptable toxicity.
None Documented
None Documented
3–4 hours in patients with normal renal function; prolonged to 8–12 hours in moderate to severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal elimination half-life is approximately 3.6 hours (range 1.6–7.1 hours) in patients with epithelioid sarcoma at steady state. Short half-life supports twice-daily dosing. Consider accumulation with renal or hepatic impairment.
Renal: approximately 50% of absorbed dose excreted unchanged in urine. Biliary/fecal: up to 20% excreted in feces as metabolites, with less than 5% as unchanged drug.
Primarily hepatobiliary excretion: approximately 70% of the dose recovered in feces as unchanged drug and metabolites, with <1% excreted renally as unchanged tazemetostat.
Category C
Category C
Antineoplastic
Antineoplastic, EZH2 Inhibitor